Brief: Nykode Therapeutics: mRNA-LNP Cancer Vaccine Demonstrates Superior Efficacy
June 11 (Reuters) - Nykode Therapeutics ASA NYKD.OL :
* NYKODE THERAPEUTICS ANNOUNCES MRNA-LNP CANCER VACCINE
DEMONSTRATES SUPERIOR EFFICACY
* LATEST STUDY DEMONSTRATED THAT APC-TARGETED VACCINE
CONSISTENTLY
ACHIEVED BROADER AND MORE ROBUST IMMUNE RESPONSE ACROSS DOSES
COMPARED TO UNTARGETED NEOANTIGEN VACCINE
Source text for Eikon: ID:nObiCZYMXa
Further company coverage: NYKD.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Nykode Therapeutics ASA
See all newsRCS - Accession Theraptcs. - Accession Therapeutics: Board appointments
Brief: Nykode Therapeutics Mulls Private Placement
Brief: Nykode Receives Draft Recommendation In Tax Case
Brief: Nykode Therapeutics Receives U.S. Vaccine Patent
Brief: Nykode Therapeutics Expects Draft Recommendation From Norwegian Tax Appeal Board In August 2026